Generation of patient-specific induced pluripotent cells (iPSCs) holds great promise for regenerative medicine. Epstein-Barr virus (EBV) immortalized lymphoblastoid B cell lines (LCLs) can be generated from a minimal amount of blood and are banked worldwide as cellular reference material for immunological or genetic analysis of pedigreed study populations. We report the generation of iPSCs from two LCLs (LCLiPSCs) via a feeder-free episomal method using a cocktail of transcription factors and small molecules. LCL-derived iPSCs exhibited normal karyotype, expressed pluripotency markers, lost oriP/EBNA-1 episomal vectors, generated teratomas, retained donor identity and differentiated in vitro into hematopoietic, cardiac, neural and hepatocyte-like lineages. Significantly, although the parental LCLs express viral EBNA-1 and other EBV latency related elements for their survival, their presence was not detectable in LCL-iPSCs. Thus reprogramming LCLs could offer an unlimited source for patient-specific iPSCs.
Introduction
Patient-specific induced pluripotent stem cells (iPSCs) can serve as useful models for understanding the etiology of disease and facilitating the development of novel therapeutic interventions 1 . B cells represent a larger fraction of the PBMC population (~20%) and can be transformed in vitro by Epstein-Barr virus (EBV) to generate lymphoblastoid cell lines (LCLs) using as little as 0.5mL blood 2 , creating a unlimited proliferative source of cells for reprogramming trials. LCLs are a precious resource for immunological, epidemiological and rare disease studies. A number of facilities manage collections of LCLs available internationally to researchers 2 . Thus, generating iPSCs from LCLs offers the advantage of working with minimal amounts of blood from living donors as well as frozen LCL collections banked worldwide.
The capability to reprogram terminally differentiated cells depends on the inherent physiological plasticity of the cell type. B lymphocytes can transdifferentiate to macrophages [3] [4] or hematopoietic precursor cells (HPCs) after down-regulation of Pax5 expression 4 . Murine B cells have been reprogrammed to iPSCs via viral transduction of reprogramming factors with 5 and without Pax5 inhibition 6 . Generating iPSCs via nonviral, non-integrating methods is appealing to generate clinically useful iPSCs. Recently, iPSCs have been generated by delivering the reprogramming factors via oriP/EBNA-1 based plasmids in fibroblasts and peripheral blood CD34+ cells [7] [8] . The inherent plasticity of B cells, their receptivity to oriP/EBNA-1 plasmids, ease of generating LCLs, and availability of banked LCL collections inspired our efforts to reprogram LCLs using oriP/EBNA-1-based vectors.
LCL-derived iPSCs (LCL-iPSCs) demonstrated the characteristics of pluripotent stem cells, a normal karyotype, the genetic identity and IgGH signature of the parental LCLs, and lost expression of the episomal reprogramming genes as well as viral genes, For personal use only. on July 16, 2017 . by guest www.bloodjournal.org From leading to self-sustained LCL-iPSCs essentially free of exogenous reprogramming and viral elements.
Methods
Detailed methods are included in Document S1. All animal experiments were conducted according to relevant national and international guidelines under the approval of the Cellular Dynamics International Animal Care and Use Committee.
Briefly, LCLs obtained from Coriell Cell Repository (GM02254 and GM22649) were transfected using oriP/EBNA-1-based vectors 9-10 then placed on Matrigel-coated plates (BD Biosciences) in reprogramming medium (RM) 11 for 2-3 weeks followed by TeSR-2 (Stem Cell Technologies) for an additional 2 weeks. After handpicking, the iPSC-like colonies were propagated with TeSR-2 on Matrigel-coated plates. Characterization of four LCL-iPSCs was performed by flow cytometry, RT-PCR and teratoma analysis 9 . In vitro differentiations were performed to neural, hematopoietic, cardiac, and hepatocytelike lineages. The presence of EBV was assessed by RT-PCR, immunohistochemistry and quantitative PCR (Q-PCR) (UNC-Department of Pathology). G-banding of LCLiPSCs (WiCell Research Institute) and IgGH receptor rearrangement analysis (Hematologics) on parental and LCL-iPSCs were performed and short tandem repeat analysis confirmed genetic identity to the parental LCLs (Cell Line Genetics).
Results and Discussion
LCLs were reprogrammed to iPSCs via a single transfection of oriP/EBNA-1 plasmids encoding reprogramming genes under feeder-free conditions previously described 11 . LCLs were placed on Matrigel-coated plates after transfection, and cultured with RM until adherent colonies were visible ( Figure 1A ) and then transitioned to TeSR-2. After ~2 weeks of culturing in TeSR-2, the pluripotent status of the colonies were assessed by live-cell staining of Tra-1-60 ( Figure 1Ci ). 2-23% of total adherent colonies by day 35 were confirmed to be iPSCs by Tra-1-60 staining. Various combinations of reprogramming plasmids were capable of reprogramming LCLs ( Figure 1B , S1 Table 1 ); a minimal combination of OCT3/4, SOX2, NANOG, and SV40-T antigen was sufficient to reprogram LCLs. This method is more efficient than the average efficiency of viral reprogramming terminally differentiated murine B cells 6 , but not as efficient as episomal reprogramming of human fibroblasts or cord blood 11 (S1 Table 2 ). The amenability of LCLs to episomal reprogramming could be dependent on the broad rearrangement of chromatin architecture orchestrated by EBNA-1 to create an 'open' chromatin state during the immortalization of B cells by EBV 12 . These pleotrophic effects of EBNA-1 and expression of other viral proteins may favor reprogramming of LCLs compared to primary cells 13 .
Extensive characterization was performed on two clones derived from LCL-1 (LCLiPS1a and LCL-iPS1b), and two from LCL-2 (LCL-iPS2a and LCL-iPS2b). These clones had (Figure 1Civ ). IgGH profiles can serve as a clone tracking tool for LCL-iPSCs and their derivatives [14] [15] . RT-PCR confirmed expression of pluripotency-associated transcripts ( Figure 1Cii , S1 Figure 1 ) and absence of reprogramming elements ( Figure 1D -E, S1 Figure 2 ). All four LCLiPSCs maintained in the presence of TeSR-2 for over 25 passages generated welldifferentiated teratomas, revealing the presence of cartilage (mesoderm), goblet cells (endoderm) and neural rosettes (ectoderm) ( Figure 2D ). In vitro differentiation of LCLiPSCs was performed to assess their endodermal, ectodermal and mesodermal potential. Generation of Since EBNA-1 is required for establishment of latent EBV infection and long-term survival of LCLs [16] [17] , and is the only viral protein required for persistence of EBV in host cells, LCL-iPSCs were tested for the presence of EBNA-1. EBNA-1 was not detectable at the transcriptional and protein levels in the LCL-iPSCs after 25 passages (Figure 2A-B) . In addition, no expression of other viral genes: EBNA-2, LMP-2A, and BZLF-1 (Figure 2A) or the viral sequences associated with these genes (S1 Figure 2) was detectable, further supporting the loss of EBV from LCL-iPSCs.
Earlier reports [18] [19] have described the unequal partitioning of EBV in the absence of viral selection in daughter cells. To detect the rate of loss of EBV-associated viral elements in LCL-iPSCs, real-time quantitative PCR (Q-PCR) was performed to measure viral load in parental LCLs and LCL-iPSCs. The quantification of three EBV genome segments (EBNA-1, EBER1, BamH1W) was performed along with a control human gene (APOB) by which to normalize between samples 20 . The absolute copy number of the EBV-associated viral elements present at various passage numbers was curve fitted to a general exponential function y=b*f n , where y refers to the copies of viral elements (either EBNA-1, EBER1 or BamH1W) per cell for passage n (of LCL-iPSCs), f is the fraction of daughter cells that contain the virus per passage, and both b and f were chosen to fit the data. The results demonstrated that only 46% EBNA-1 (Figure 2Ci For
We conclude that episomal reprogramming of LCLs leads to accelerated loss of EBV to generate EBV-free LCL-iPSCs which can be used to generate defined cell lineages. LCL-iPSCs can serve as a valuable tool to further researching a myriad of immunological, epidemiological and rare disease studies.
19.
Vereide iv. Each B-cell has a respective single productive immunoglobulin gene rearrangement that is unique in both length and sequence. Polymerase chain reaction (PCR) assays with specific primers for the joining region and all three of the conserved framework regions (FR1, FR2 and FR3) were used to amplify immunoglobulin heavy chain (IgGH) gene rearrangements according to the BIOMED-2 Concerted Action protocol. DNA from a normal or polyclonal B cell population produces a bell-shaped curve of amplicon products (Gaussian For personal use only. on July 16, 2017. by guest www.bloodjournal.org From distribution), whereas clonal rearrangements are identified as prominent, singlesized products by capillary electrophoresis and GeneScanning. v. Karyotype analysis of each iPSC line was performed after 11 passages, and found to be normal (a representative image of LCL-iPS2b is shown).
(D) RT-PCR analysis of RNA from LCL-iPSCs for the expression of reprogramming vector genes at passage 25. Forward primers for three reprogramming genes of interest (OCT4, NANOG and c-MYC) and reverse primers for IRES2 were utilized. GAPDH was used as a positive loading control for each sample and cDNA made in the absence of Reverse Transcriptase (no RT) was used to verify that genomic DNA did not contaminate the RNA samples. A reprogramming vector was included as a positive control for each PCR reaction (+ control).
(E) PCR analysis of genomic DNA confirms no integration of the transgenes in LCLiPSCs at passage 25. Forward primers for three reprogramming genes of interest (OCT4, NANOG and c-MYC) and reverse primers for the IRES were utilized. GAPDH was used as a positive loading control for each sample and a reprogramming vector was included as a positive control for each PCR reaction (+ control).
Figure 2. Analysis of LCL-iPSCs for reprogramming and viral elements and trilineage differentiation of LCL-iPSCs.
(A) RT-PCR analysis of H1 (hESC line), LCL-1, LCL-2 and two representative LCLiPSC clones from each donor line at passage 25 for expression of EBV genes: EBNA-1, EBNA-2, LMP-2A and BZLF-1. GAPDH was used as a positive loading control for each sample and cDNA made in the absence of Reverse Transcriptase (no RT) was used to verify that genomic DNA did not contaminate the RNA samples.
(B) Immunohistochemistry was performed on LCL-1, LCL-2 and two representative LCL-iPS clones from each donor line using an anti-EBNA-1 antibody to detect EBNA-1 protein expression (brown). Images were captured using 100x magnification.
(C) EBV loss during reprogramming is confirmed by quantitative PCR (Q-PCR). The viral load during reprogramming was evaluated by harvesting genomic DNA harvested at various passages during the reprogramming. Q-PCR was performed using primers and TaqMan probes targeted three EBV gene segments: BamH1W, EBNA-1, and EBER1. The human APOB gene was used for normalization and the loss of EBNA-1 (i), EBER1 (ii) or BamH1W (iii) was fitted to a general exponential function y=b*fn, where y refers to the copies of viral elements (either EBNA-1, EBER1 or BamH1W) per cell for passage n, f is the fraction of daughter cells that contain the virus per passage, and both b and f were chosen to fit the data. 
